Clinical trials: Primary Open-angle Glaucoma
Ocular Hypertension, Primary Open-angle Glaucoma
BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension
The purpose of this study is to evaluate the clinical efficacy of the BREMEN eye drops in the treatment of primary open-angle glaucoma or intraocular hypertension.
- Trial name
- NCT03235232
- Testing
- BREMEN eye drops, Combigan®
- Where
- Brazil
- Volunteers
- 406 people
- Sponsor
- EMS
Primary Open Angle Glaucoma
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100R/L in subjects previously enrolled in Glaukos Study GC-003.
- Trial name
- NCT01836042
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma
A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
- Trial name
- EVOLVE (NCT06407973)
- Testing
- OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sight Sciences, Inc.
Primary Open Angle Glaucoma (POAG)
iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.
- Trial name
- NCT03478293
- Testing
- iStent inject surgery
- Where
- Brazil
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma, Ocular Hypertension
Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Reduction of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- ANGEL-2 (NCT04742283)
- Testing
- DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- 41 sites in United States
- Volunteers
- 323 people
- Sponsor
- Santen Inc.
Open Angle Glaucoma
Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma
The goal of the study is to prospectively evaluate and compare Hydrus microstent to the iStent Inject Wide in combination with cataract surgery in patients with mild to moderate open angle glaucoma.
- Trial name
- NCT05583591
- Testing
- Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Diablo Eye Associates
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Phase III trial involving topical application, in both eyes, of trabodenoson ophthalmic formulation 3.0% or 6.0% once per day or 4.5% twice per day, placebo twice per day, or timolol 0.5% twice per day for 12 weeks in adult…
- Trial name
- MATrX-1 (NCT02565173)
- Testing
- trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD
- Where
- United States
- Volunteers
- 303 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Subject With Primary Open-angle Glaucoma (POAG)
A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent
The purpose of this study is to assess the efficacy and safety of one iStent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.
- Trial name
- NCT01252914
- Testing
- iStent Supra Stent
- Where
- Armenia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Primary Open-angle Glaucoma
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
Objectives: To evaluate the non-inferiority in the intraocular pressure decrease of the preservative-free ophthalmic solution PRO-122, manufactured by Laboratorios Sophia S.A.
- Trial name
- PRO-122LATAM (NCT03193333)
- Testing
- PRO-122, Timolol eye drops, Dorzolamide-Timolol Ophthalmic
- Where
- 2 sites in Colombia, Mexico
- Volunteers
- 51 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension
Aim: To demonstrate the non-inferiority of the PRO-067 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus GAAP Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- COMPLIANCE (NCT02801617)
- Testing
- PRO-067, GAAP Ofteno®
- Where
- Mexico
- Volunteers
- 116 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Ocular Hypertension, Primary Open Angle Glaucoma
Glaucoma Adherence Study
The purpose of this study is evaluate adherence to DuoTrav® when reinforced by the use of the Travalert™ Dosing Aid.
- Trial name
- GAS (NCT00676637)
- Testing
- Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav), Travalert Dosing Aid
- Where
- 4 sites in France, Italy and 2 more
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Glaucoma, Narrow Angle
Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with…
- Trial name
- SAFARI 3 (NCT05236439)
- Testing
- Interposition supraciliary implant
- Where
- Armenia
- Volunteers
- 57 people
- Sponsor
- Ciliatech
Primary Open Angle Glaucoma
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity.
- Trial name
- NCT01539239
- Testing
- Hydrus Aqueous Implant, Cataract surgery
- Where
- 38 sites in United States, Canada and 7 more
- Volunteers
- 1,143 people
- Sponsor
- Ivantis, Inc.
Primary Open-angle Glaucoma and Ocular Hypertension
DE-117 Spectrum 5 Study
Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
- Trial name
- NCT03697811
- Testing
- DE-117 Ophthalmic Solution
- Where
- 32 sites in United States
- Volunteers
- 107 people
- Sponsor
- Santen Inc.
Primary Open-Angle Glaucoma (POAG)
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma
This is an investigator initiated, single center, open label, non-randomized, exploratory clinical study. The purpose is to assess the safety and preliminary efficacy of gene therapy GVB-2001 (ScAAV2-dnRhoA) delivered via…
- Trial name
- NCT06921317
- Testing
- GVB-2001-high dose, GVB-2001-low dose
- Where
- China
- Volunteers
- 6 people
- Sponsor
- IVIEW Therapeutics Inc.
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of Triple Combination Therapy compared with Fixed Combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01241240
- Testing
- bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy), Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution
- Where
- 2 sites in Colombia, Mexico
- Volunteers
- 192 people
- Sponsor
- Allergan
Primary Open-angle Glaucoma
Safety and Effectiveness of VISULAS Green Selective Laser Trabeculoplasty (SLT)
An interventional, open, prospective, multi-center pre-market clinical investigation according to §§20-23a Medizinproduktegesetz (MPG, medical devices act), in which a total of 40 eyes of 40 consecutive patients at up to five (5)…
- Trial name
- NCT04519814
- Testing
- selective laser trabeculoplasty (SLT)
- Where
- 5 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Carl Zeiss Meditec AG